GnRH antagonists (e.g., relugolix) for symptom management

Type: drug

Status: FDA Approved (for related conditions)

Developer: Myovant Sciences (now Sumitomo Pharma)

Breakthrough Summary

No summary available.

Mechanism of Action

Details pending.

Year: 2026